Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

YOU WONT BELIEVE: Kyowa kirin | Mind Blowing Facts

Nine More Drugmakers Join the Medicaid Pricing Deals, and the Effect on Your Pharmacy Bill Is Limited

Nine more drugmakers signed most-favored-nation Medicaid pricing deals, bringing the total to 26. Here is what changes and what does not.

Medical Daily

Trump Has Now Struck Drug Pricing Deals With 26 Companies. They Cover Nearly 90% Of The Branded Drug Market.

Nine midsize drugmakers joined the White House program and pledged at least $19.6 billion in U.S. manufacturing investments.

International Business Times

Kyowa Kirin to Present New Complementary Evidence Further Defining Clinical Utility of Mogamulizumab in Cutaneous T-Cell Lymphoma at 2026 WCCL

PRINCETON, N.J., June 10, 2026 (GLOBE NEWSWIRE) -- Kyowa Kirin, Inc., a wholly owned subsidiary of Kyowa Kirin Co. Ltd (TSE: 4151), today announced new data further defining the potential of mogamulizumab in the treatment of relapsed or refractory mycosis fungoides and Sézary syndrome, two subtypes of cutaneous T-cell lymphoma,…

AAP

From analysis to the latest developments in health,
read the most diverse news in one place.

Kura Oncology Q1 Earnings Call Highlights

Kura Oncology (NASDAQ:KURA) reported $5.8 million in first-quarter net product revenue from KOMZIFTI, its first commercial product, and said the launch is showing early signs of physician uptake, broad payer coverage and use in combination regimens, according to management’s earnings call for the fi

MarketBeat

1 Under-$10 Stock Set to Surge as Much as 850% in 2026

Kura is a classic high-risk, high-reward biotech investment that has entered a vital growth phase.

Barchart

Kura Oncology Scores $30 Million Boost As New Leukemia Drug Enters Major Trial

Kura Oncology, Inc. (NASDAQ:KURA) shares rose Friday after the biotechnology firm confirmed a $30 million milestone payment from its collaboration with Kyowa Kirin.

Benzinga

Amgen Rocatinlimab's Data Shows Potential As Long-Term Therapy For Atopic Dermatitis

Amgen Inc. (NASDAQ:AMGN) and Kyowa Kirin released preliminary topline results from the ASCEND study evaluating rocatinlimab in adults and adolescents with moderate to severe atopic dermatitis (AD) on Tuesday.

Benzinga

Read news from The Economist, FT, and more,
with one subscription

Kyowa Kirin's Gene Therapy: Most Expensive US Drug

Kyowa Kirin's .3 million gene therapy sparks debates on accessibility and affordability in healthcare.

Top News

Kyowa Kirin, Ardelyx Amend Tenapanor Pact In Cardiorenal Disorders

Ardelyx Inc (NASDAQ: ARDX) has

Benzinga

People

Donald Trump

212,687 stories

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.